# Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

> **NCT04052555** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (estimated)

## Conditions studied

- Bilateral Breast Carcinoma
- HER2-Negative Breast Carcinoma
- Localized Breast Carcinoma
- Recurrent Breast Carcinoma
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Berzosertib
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04052555
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-24
- **Primary completion:** 2027-02-24
- **Final completion:** 2027-02-24
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052555, "Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT04052555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*